#United States #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals Faces Legal Challenge

In an alarming development within the biopharmaceutical sector, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is currently embroiled in a legal battle due to accusations of violating securities laws. The Gross Law Firm has announced that it is seeking shareholders of the company who may have been adversely affected to come forward.

Overview of Allegations

The lawsuit alleges that Rocket Pharmaceuticals misled investors by providing overly optimistic statements about its product, RP-A501, while failing to disclose crucial risks that were associated with its clinical trials. Specifically, it is reported that the firm did not communicate the fact that serious adverse events (SAEs), including participant fatalities, could occur during the trial.

The central concerns include:

• - The issuance of misleading statements that inflated the company’s stock prices.
• - Concealment of key information surrounding safety protocols during the clinical trials, notably the introduction of a new immunomodulatory agent without timely updates to shareholders.
• - Lack of transparency regarding a serious incident that led to a clinical hold placed by the FDA on RP-A501's Phase 2 pivotal study.

The culmination of these issues was apparent when, on May 27, 2025, Rocket Pharmaceuticals disclosed that the FDA had halted the study after a participant experienced severe adverse effects, eventually leading to death. The failure to inform investors about critical amendments and the risks involved raised significant concerns about the company’s corporate governance and accountability.

Stock Price Impact

The announcement resulted in a dramatic decline in the company's stock price. On May 23, 2025, Rocket’s shares were valued at $6.27 each; however, within just one trading day post-announcement, the price plummeted to $2.33—a staggering 37% drop.

Steps for Affected Shareholders

Shareholders who acquired shares during the specified class period from September 17, 2024, to May 26, 2025, are encouraged to register with The Gross Law Firm. Participating in the lawsuit does not necessitate leading the case as a lead plaintiff, and the law firm asserts that there will be no upfront costs involved in joining the class action.

The deadline for potential lead plaintiff applicants is set for August 11, 2025, thereby providing a limited window for investors to act. Those affected will receive ongoing status updates through the firm’s portfolio monitoring software commendably aimed at keeping them informed throughout the proceedings.

Why Choose The Gross Law Firm?

The Gross Law Firm is known for its commitment to advocating for investor rights. Their approach focuses on addressing corporate malpractices and seeking reparation for parties adversely affected by deceitful actions. The firm takes pride in its role as a guardian of investor trust and corporate accountability.

For shareholders impacted by this event, acting swiftly is vital. Register today to ensure you don’t miss crucial updates regarding the case and the opportunity for potential recovery.

Contact Information

For further inquiries or to initiate your registration, contact The Gross Law Firm at:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018

In this swiftly changing landscape of biopharmaceutical stocks, staying informed is crucial. As Rocket Pharmaceuticals navigates this turbulent period, investors must remain vigilant and proactive in safeguarding their interests.